Estrogen receptor (ER) mutations are common in primary endometrial cancer. However, ER mutant-driven oncogenic mechanisms in endometrial cancer are poorly understood. In their study, Blanchard and colleagues inserted common endometrial cancer mutations ER-Y537S and ER-D538G into endometrial cancer cell lines using CRISPR/Cas9 and assessed their mechanistic and phenotypic effects. RNA-Seq analysis revealed mutant-specific transcriptional programs. Correspondingly, ChIP-Seq analysis identified unique ER-Y537S and ER-D538G genomic binding sites, and ATAC-Seq analysis showed that the mutants alter chromatin accessibility in distinct loci. Both mutants enhanced endometrial cancer cell proliferation in vivo, and ER-Y537S enhanced tumor growth and metastasis in a mouse model as well. To discover potentially targetable ER cofactors in endometrial cancer, the authors performed rapid immunoprecipitation and mass spectrometry of endogenous proteins (RIME) in wild-type and mutant ER-expressing endometrial cancer cells. The authors identified cyclin dependent kinase 9 (CDK9) as an ER cofactor in endometrial cancer and demonstrated that pharmacologic...
Skip Nav Destination
Article navigation
1 October 2023
Highlights|
October 02 2023
Selected Articles from This Issue Available to Purchase
Online ISSN: 1557-3125
Print ISSN: 1541-7786
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
Mol Cancer Res (2023) 21 (10): 993.
Citation
Selected Articles from This Issue. Mol Cancer Res 1 October 2023; 21 (10): 993. https://doi.org/10.1158/1541-7786.MCR-21-10-HI
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Purchased this content as a guest? Enter your email address to restore access.
Please enter valid email address.
Pay-Per-View 24-Hour Access
$50.00
110
Views
Citing articles via
Advertisement